This page shows the latest Pfizer/BioNTech news and features for those working in and with pharma, biotech and healthcare.
One vaccine is monovalent and the other is bivalent, made up from a combination of the Pfizer/BioNTech COVID-19 vaccine and a vaccine candidate designed to target the spike protein ... The Pfizer/BioNTech COVID-19 vaccine, which is based on BioNTech’s
The data shows that a booster dose of both Omicron-adapted vaccines gave a considerably higher immune response against Omicron BA.1, compared to Pfizer/BioNTech’s current COVID-19 vaccine. ... One vaccine is monovalent and the other is bivalent, made
Pfizer and BioNTech’s COVID-19 vaccine has been given emergency use authorisation by the US Food and Drug Administration (FDA) for children aged six months through to four years old. ... The three 3µg doses of the Pfizer/BioNTech COVID-19 vaccine
Pfizer and BioNTech have announced recent data from a top-line safety, immunogenicity and vaccine efficacy phase 2/3 trial assessing a third 3µg dose – one-tenth of the adult dosage – ... It was found that this dosage of the Pfizer/BioNTech COVID-19
Pfizer/BioNTech have been given an expanded emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) for its COVID-19 vaccine. ... It is the same formulation and strength as previous Pfizer/BioNTech COVID-19 vaccine doses.
In a recent interview, Pfizer CEO Albert Bourla told CNBC that the company plans to submit an application of data to the US Food and Drug Administration (FDA) highlighting the need ... In January Pfizer/BioNTech began a study to evaluate the safety of an
More from news
Approximately 81 fully matching, plus 131 partially matching documents found.
In the UK, the looming Brexit sparked new models of regulatory approval and fast-track opportunities, as recently observed in the rapid approval of Pfizer’s COVID-19 vaccine. ... So far the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford University
Beyond the connection between HCPs and pharma or NGOs, it is encouraging to see collaborations such as Clover and GSK evaluating a vaccine candidate and Pfizer and Biontech doing the same. ... A number of top pharma companies are included in the newly
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
This work is ongoing as the virus mutates; last month, it was announced that Pfizer and BioNTech had started clinical trials for a new Covid vaccine targeting the Omicron variant.
In the past year, we have seen partnerships between companies such as Pfizer and BioNTech; Oxford University and AstraZeneca and more recently GSK and CureVac. ... doi:10.1136/bmj.n129. 24. Dean G, Reuters. The UK approved Pfizer’s vaccine too quickly
Both the Oxford/AstraZeneca and Pfizer/BioNTech vaccines were developed using platform technologies which didn’t exist 20 years ago, allowing these vaccines to be developed much faster.
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so
Health Products Regulatory Agency’s speedy approval of the Pfizer-BioNTech COVID-19 vaccine in the UK. ... A good example is a recent incident in the UK that made headline news, where two NHS workers who were among the first to receive the
More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...